Pharma more optimistic about future despite Upcoming industry consolidation
Representing the views of 1600 global participants from all sectors of pharma, ‘The Industry Healthcheck’ provides a unique insight into the sector, highlighting both key concerns and hopes for the future.
More than 69% of senior players within the pan-world pharma industry expect to see a year-on-year increase in profits in 2014 while, longer term, 89% expect to see further shrinkage in the sector due to consolidation. Over 42% expect investment in R&D to also reduce, according to the new ‘Industry Healthcheck’, an extensive global survey undertaken by eyeforpharma.
Pharma’s reputation is still a key concern. Less than 22% thought it was improving amongst the general public. This increased to over 35% amongst healthcare professionals, but still a low figure. Yet pharma didn’t consider itself entirely at fault: nearly 34% claimed that the industry was being hamstrung by the tight regulatory structure that prevents it from defending its own corner.
Despite this, the vast majority of respondents (over 70%) were committed to a career within pharma, stating an intention of remaining in the sector throughout their working life.
“We really wanted to litmus-test some of the key concerns throughout the industry and we were truly amazed how many pharma executives from countries throughout the world leapt at the opportunity to take part in such a detailed and extensive survey,” says Paul Simms, Chairman of eyeforpharma.
“The result is certainly the most up-to-date and possibly, the most extensive survey undertaken from within the pharma industry on the future of the sector.”
The full results from the eyeforpharma ‘Industry Healthcheck’ are available here -http://www.eyeforpharma.com/healthcheck2014
END
For further information contact:
Lindsay Morgan on 07971 553375 or email